Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome

• Published in: Progress in neuro-psychopharmacology & biological psychiatry Vol. 40; pp. 326 - 333
• Main Authors: Inoue, Yuichi, Hirata, Koichi, Hayashida, Kenichi, Hattori, Nobutaka, Tomida, Takayuki, Garcia-Borreguero, Diego
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Inc 10.01.2013; Elsevier
• Subjects: Adult; Aged; Application site reactions; Asian Continental Ancestry Group; Augmentation; Biological and medical sciences; Dopamine Agonists - adverse effects; Dopamine Agonists - therapeutic use; Female; Humans; Male; Medical sciences; Middle Aged; Nervous system (semeiology, syndromes); Nervous system as a whole; Neurology; Neuropharmacology; Pharmacology. Drug treatments; Quality of life; Responder rate; Restless legs syndrome; Restless Legs Syndrome - drug therapy; Rotigotine; Severity of Illness Index; Tetrahydronaphthalenes - adverse effects; Tetrahydronaphthalenes - therapeutic use; Thiophenes - adverse effects; Thiophenes - therapeutic use; Treatment Outcome; Application site reactions; SAS; LOCF; MedDRA; MPI; ECG; NIH; ASRS; QOL; SF-36; Quality of life; Augmentation; SD; Restless legs syndrome; IRLS; RLS; Rotigotine; FAS; JESS; Responder rate; IRLSSG; PSQI; Sensitivity disorder; Agonist; Nervous system diseases; Dopamine receptor; Toxicity; D1 Dopamine receptor; Antiparkinson agent; D3 Dopamine receptor; D2 Dopamine receptor; Efficiency; Dopamine agonist; Risk factor; Safety; Neurological disorder

The present study aimed to examine the long-term efficacy and safety of rotigotine treatment for restless legs syndrome (RLS), as well as the rate of clinically significant augmentation, in a 1-year open-label study of Japanese subjects. Japanese patients with RLS who had been treated with rotigotin...